Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics gross margin
Gross margin is gross profit as a percentage of revenue.
Myriad Genetics's gross margin for the twelve months ending Jun 30, 2026 was 68.8%. For fiscal 2025 it was 69.9%, against 69.9% the year before. The highest annual figure on record is 89.6% in fiscal 2012.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 69.9% | +0.0 |
| FY2024 | Dec 31, 2024 | 69.9% | +1.2 |
| FY2023 | Dec 31, 2023 | 68.6% | −1.6 |
| FY2022 | Dec 31, 2022 | 70.2% | −9.9 |
| FY2017 | Jun 30, 2017 | 80.1% | −2.0 |
| FY2016 | Jun 30, 2016 | 82.1% | +0.4 |
| FY2015 | Jun 30, 2015 | 81.6% | −6.0 |
| FY2014 | Jun 30, 2014 | 87.7% | −1.8 |
| FY2013 | Jun 30, 2013 | 89.5% | −0.1 |
| FY2012 | Jun 30, 2012 | 89.6% | +1.0 |
| FY2011 | Jun 30, 2011 | 88.6% | +0.9 |
| FY2010 | Jun 30, 2010 | 87.8% | +1.0 |
| FY2009 | Jun 30, 2009 | 86.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | 66.6% | −4.6 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | 68.7% | +0.2 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | 70.0% | −1.7 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | 69.9% | −0.3 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | 71.2% | +1.7 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | 68.5% | +0.5 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | 71.7% | +3.0 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | 70.2% | +0.2 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | 69.6% | +1.0 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | 68.1% | +0.7 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | 68.7% | −1.0 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | 70.0% | +2.2 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | 68.5% | −3.8 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | 67.3% | −3.6 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | 69.7% | −10.2 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | 67.8% | −12.2 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | 72.3% | −7.5 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | 70.9% | −11.2 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | 79.9% | −0.6 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 79.9% | −1.1 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | 79.8% | −1.1 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | 82.1% | +1.9 |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | 80.5% | −1.8 |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | 81.0% | −1.4 |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | 80.8% | −2.3 |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | 80.2% | −2.9 |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | 82.4% | +0.7 |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | 82.4% | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | 83.2% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | 83.1% | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | 81.7% | – |
See a number that looks wrong?